Multinationals decreased Israeli R&D spending during crisis

Central Bureau of Statistics reveals that in midst of global financial crisis, Israeli subsidiaries of multinationals reduced R&D spending.

By NADAV SHEMER
August 8, 2012 23:23
1 minute read.
US dollars

US dollars 390. (photo credit: Thinkstock/Imagebank)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Israeli subsidiaries of multinational corporations drastically reduced research and development (R&D) spending in the middle of the global financial crisis, the Central Bureau of Statistics revealed Wednesday.

The Israeli foreign-controlled affiliates, including the local branches of Intel, Microsoft and IBM, spent $4.7 billion dollars on R&D activities in 2009, an 8 percent decrease from the previous year, but 36% increase from 2006. They contributed 62% of the Israeli business sector’s total R&D expenditure in 2009.

Be the first to know - Join our Facebook page.


R&D data is published with a lag as the CBS gives companies time to complete their financial reports before surveying them.

“IN” companies, as the Israeli foreign- controlled affiliates are known, directed just 14% of overall spending toward R&D in 2009, a 1% drop from 2008. Similarly to previous years, 64% of their R&D expenditure went toward paying wages and other employment costs, and 23% of their workforce was involved in R&D activities.

They continued to dominate exportation, making $3.4b. in R&D-related sales abroad, which constituted 92% of total Israeli R&D exports. Naturally, they had an advantage: 90% of their exports went directly to their foreign parent companies, and 72% of their exports were directed to the United States.

The study also surveyed Israeli parent companies with foreign subsidiaries, also known as “OUT” companies, and found that they spent $3.5b. on R&D in 2009. Unlike the IN companies, which concentrated most of their R&D spending in the area of computing services, the OUT companies focused mainly on industry.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS